In most cancers, the activation of NF‐κB is enhanced, and this enhancement in NF‐κB activation is often due to increased stimuli of the NF‐κB pathway, such as increased TNFα and IL‐1 in the tumor microenvironment.281, 282. The gene discussed is IL1B; the disease is neoplasm.